Breethe’s mission is to develop and commercialize the world’s first wearable artificial lung. Lung failure is a progressive and debilitating disease that contributes to the death of 270,000 people in the United States alone each year. The options available for physicians treating end-stage lung failure are limited, and do not provide the lung support required for healing and effective rehabilitation.
The Breethe OXY-1 System will provide a new treatment option for patients who suffer from acute and chronic lung failure.
We have identified three specific patient conditions that frequently lead to acute respiratory failure:
- Acute Respiratory Distress Syndrome (ARDS)
- Chronic Obstructive Pulmonary Disease (COPD)
- Idiopathic Pulmonary Fibrosis (IPF)
These diseases result in approximately 270,000 non-cancer lung failure related deaths in the United States each year. Breethe’s aim is to develop a solution that will improve patient outcomes and quality of life to approximately 50,000 patients annually in these categories alone.
The United States represents about 43% of the global medical device market, and we believe that there is substantial opportunity outside of the US.
Breethe was formed in May 2014 and is a spin-out from the University of Maryland, Baltimore
(UMB). The Company has entered into a Master License Agreement with UMB which provides
certain license and other rights with respect to four different “families” of patent applications
which cover key elements of the ambulatory oxygenation system being developed by Breethe.